Patients with Ankylosing Spondylitis Don’t Fully Trust Biosimilars
According to a story from ankylosingspondylitisnews.com, a significant proportion of patients stopped taking a biosimilar for infliximab within six months of transitioning to the new medication. This suggests that the…